A novel prognostic biomarker in progression free survival for patients with cervical cancer, glucose to c-reactive...

Area of Science:

• Oncology
• Biomarkers
• Cancer Research

Background:

• Cervical cancer presents high morbidity and mortality.
• Inflammatory and metabolic markers are increasingly recognized for their impact on survival outcomes.
• The glucose/C-reactive protein ratio (GCR) combines inflammatory and glycemic status.

Purpose of the Study:

• To investigate the prognostic value of the glucose/C-reactive protein ratio (GCR) for progression-free survival (PFS) in cervical cancer patients.
• To evaluate the association of GCR with overall survival (OS) and mortality.
• To compare GCR between cervical cancer patients and healthy individuals.

Main Methods:

• Retrospective analysis of 90 cervical cancer patients (adenocarcinoma and squamous cell carcinoma).
• Kaplan-Meier analysis for PFS and OS, comparing clinical, inflammatory, and glycemic parameters.
• Independent t-test for comparison with 90 healthy controls; ROC curves for mortality prediction.

Main Results:

• Glucose, C-reactive protein (CRP), CRP/lymphocyte ratio (CLR), and GCR were significant predictors of mortality.
• Disease stage, glucose, CRP, CLR, and GCR were associated with OS.
• CRP, CLR, and GCR were significantly associated with PFS (p < 0.05).
• Multivariate analysis confirmed GCR as a prognostic factor for PFS (p = 0.025).
• GCR was significantly higher in cervical cancer patients compared to healthy controls (p < 0.001).

Conclusions:

• The glucose/C-reactive protein ratio (GCR) is a prognostic marker for cervical cancer, independent of disease stage.
• A higher GCR is associated with a longer progression-free survival (PFS) in cervical cancer patients.